News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

graphic showing participating states/cities on a U.S. map

EHR-based public health surveillance for chronic diseases

There are political, legal and organizational barriers to overcome but sharing data with public health could improve chronic disease

Nir Menachemi, PhD

Untreated mental illness costs Indiana more than $4 billion each year

Research team creates framework that can be applied across the U.S. A new study reveals the economic burden of

graphic showing some of the results of interhospital transfer for dementia patients

Understanding the impact of transferring patients with dementia between hospitals

Benefits may not always outweigh the risks for this vulnerable population. It is common for individuals seeking medical care